Souhaitez-vous accéder aux communiqués récents ?

Chemomab announced financial and operating results for the first quarter and provided a corporate update, including 4 presentations at DDW and EASL 2026.

Resolution Therapeutics will present key preclinical data today on its RMT RTX001 in an oral presentation at the ASGCT Annual Meeting

London, United Kingdom, April 09, 2026 (GLOBE NEWSWIRE) -- Building on the success of its inaugural year, Global Liver Institute’s A3 UK returns April 10 and 11, 2026. Delivered through a...

Geneva, Switzerland, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Today, at the 158th Executive Board meeting of the World Health Organization (WHO), Member States agreed to include the draft resolution...

Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) -- On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one of the most widespread yet under-addressed...

Third asset to advance into clinical trials, validating broad potential of Launch-iT platformAll subjects treated with first dose of AVX70371 Launch-iT, as part of multiple dosing schedule Potential...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate...

Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024Levée d’un produit brut de 116 millions d’euros dans le...

Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its...

Les résultats seront présentés lundi 18 novembre par poster lors de la session « late-breaker » du congrès de l’AASLD The Liver Meeting® à San Diego.L'étude LEGEND a atteint son critère principal...